New drugs for the treatment of tuberculosis: Needs, challenges, promise, and prospects for the future

Journal of Infectious Diseases

Volumn 205, Issue SUPPL. 2, 2012, Pages

  Lienhardt, Christian ^a,b   Raviglione, Mario ^b   Spigelman, Mel ^c   Hafner, Richard ^d   Jaramillo, Ernesto ^b   Hoelscher, Michael ^e   Zumla, Alimuddin ^f   Gheuens, Jan ^f  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF MUNICH   (Germany)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AZD 5847; BEDAQUILINE; DELAMANID; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OXAZOLIDINONE DERIVATIVE; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; SUTEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

COST EFFECTIVENESS ANALYSIS; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG SUSCEPTIBLE TUBERCULOSIS; DRUG TOLERABILITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEASIBILITY STUDY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; RISK MANAGEMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ADULT; ANTITUBERCULAR AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; DRUG AND NARCOTIC CONTROL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; TUBERCULOSIS;

EID: 84860380179     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis034     Document Type: Review

References (45)

1. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. (WHO/HTM/TB/2009.420).Geneva, Switzerland: WHO, 2009.
2. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. Geneva, Switzerland: WHO, 2011. http://whqlibdoc.who.int/publications/2011/9789241501583-eng.pdf. Accessed 10 January 2012.
3. Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med 2010; 16:186-93.
4. Ma Z, Lienhardt C, McIlleron H, Nunn A, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010; 375:2100-9.
5. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12:128-38.
6. Nunn AJ, Phillips PP, Gillespie SH. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb) 2008; 88(Suppl 1):S85-92.
7. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365:2155-66.
8. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307:223-7.
9. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitrodihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3:e466.
10. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360:2397-405.
11. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother 2009; 53:3720-5.
12. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001; 358: 1975-82.
13. Williams KN, Stover CK, Zhu T, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009; 53: 1314-19.
14. Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007; 51:1563-5.
15. Jones D, Metzger HJ, Schatz A, Waksman SA. Control of gram-negative bacteria in experimental animals by streptomycin. Science 1944; 100: 103-5.
16. Crofton J. Chemotherapy of pulmonary tuberculosis. Br Med J 1959; 1:1610-64.
17. Fox W. Whither short-course chemotherapy? Br J Dis Chest 1981; 75:331-57.
18. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3:S231-79.
19. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121:939-49.
20. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174:331-8.
21. Brindle R, Odhiambo J, Mitchison D. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001; 1:2.
22. Ginsberg AM, Spigelman M. Challenges in tuberculosis drug research and development. Nat Med 2007; 13:290-4.
23. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364:1244-51.
24. Phillips PJ, Gillespie SH, Boeree M, et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. Infect Dis 2012; 205(Suppl 2):S250-7.
25. Lienhardt C, Davies G. Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities. Int J Tuberc Lung Dis 2010; 14:528-37.
26. Sacks LV, Behrman RE. Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective. Tuberculosis (Edinb) 2008; 88(Suppl 1):S93-100.
27. Diacon A, Dawson R, Van Niekerk C, Erondu N, Ginsberg A. Phase 2 trial of a novel 3-drug regimen for both MDR-and drug-sensitive tuberculosis [poster # P-931b]. In: Program and abstracts of the 51st ICAAC, Chicago, Illinois, 17-21 September 2011. Chicago, IL: ICAAC, 2011.
28. World Health Organization. Global tuberculosis control: WHO report 2010. (WHO/HTM/TB/2010.7). Geneva, Switzerland: WHO, 2010.
29. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2010 revision. Geneva, Switzerland: WHO, 2010. http://www.who.int/hiv/pub/arv/ adult2010/en/index.html. Accessed 27 December 2011.
30. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471-81.
31. Abdool Karim S, Naidoo NP, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365:1492-501.
32. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365: 1482-91.
33. Luetkemeyer AF, Getahun H, Chamie G, Lienhardt C, Havlir DV. Tuberculosis drug development: ensuring people living with HIV are not left behind. Am J Respir Crit Care Med 2011; 184:1107-13.
34. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697-706.
35. Burman WJ, Cotton MF, Gibb DM, Walker AS, Vernon AA, Donald PR. Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens. PLoS Med 2008; 5:e176.
36. McIlleron H, Willemse M, Werely CJ, et al. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clin Infect Dis 2009; 48:1547-53.
37. http://www.cptrinitiative.org. Accessed 29 September 2011.
38. Kim PS, Makhene M, Sizemore C, Hafner R. Viewpoint: challenges and opportunities in tuberculosis research. Infect Dis 2012; 205(Suppl 2): S347-52.
39. Woodcock J, Griffin JP, Behrman RE. Development of novel combination therapies. N Engl J Med 2011; 364:985-7.
40. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Anti-InfectiveDrugsAdvisoryCommittee/ucm161856.htm. Accessed 29 September 2011.
41. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-40.
42. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993; 147:1062-3.
43. Phillips PJ, Fielding K. Surrogate markers for poor outcome to treatment of tuberculosis: results from extensive multi-trial analysis [abstract]. Int J Tuberc Lung Dis 2008; 12 (Suppl 2):S146-7.
44. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373:1183-9.
45. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180:273-80.